查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1370910

C反應蛋白檢測市場－2018-2028年全球產業規模、佔有率、趨勢、機會與預測，依檢測類型、檢測範圍、疾病領域、最終用途產業、地區、競爭細分

C-reactive Protein Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Assay Type, By Detection Range, By Disease Area, By End-Use Industry, By Region, Competition
出版日期: | 出版商: TechSci Research | 英文 189 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2022 年，全球 C 反應蛋白檢測市場價值達到 16.0101 億美元，並預計在預測期內強勁成長，預計到 2028 年年複合成長率 (CAGR) 為 2.16%，預計將達到 1835.28 美元到2028 年將達到100萬。C 反應蛋白測試是一項實驗室檢查，可評估血液中C 反應蛋白的水平。這種特殊的蛋白質是由肝臟響應身體發炎而合成的。它是人體對感染、損​​傷或其他發炎刺激的先天免疫反應的一個組成部分。通常，CRP 檢測涉及血液樣本，結果以每公升血液中 CRP 毫克數 (mg/L) 的形式報告。正常的 CRP 水平通常較低，而升高的水平可能意味著持續的發炎或感染。值得注意的是，吸煙、肥胖和某些藥物等因素也會影響 CRP 水平。 CRP 測試通常在各種醫學環境中用作發炎標記。醫療保健專業人員經常要求進行 CRP 檢測，以幫助診斷和監測一系列疾病，包括感染、自體免疫疾病、心血管疾病、創傷或手術以及治療監測。

主要市場促進因素

  • 1.發炎和傳染病的發生率不斷上升：發炎和傳染病的盛行率不斷上升，大大促進了全球C反應蛋白（CRP）檢測市場的擴大。這些疾病通常會引發免疫反應，導致血液中 CRP 水平升高。隨著這些疾病發生率的上升，醫療保健提供者越來越需要可靠的診斷工具來檢測和監測發炎。 CRP 檢測提供了一種方便有效的評估發炎程度的方法，有助於各種病症的診斷和管理。及時檢測發炎對於有效的疾病管理和併發症預防至關重要。 CRP 測試可以及早發現炎症，使醫療保健專業人員能夠在病情惡化之前進行干涉。這符合關注預防性醫療保健和早期疾病檢測的更廣泛趨勢。許多慢性疾病，例如類風濕性關節炎、發炎性腸道疾病和某些自體免疫疾病，都涉及持續的發炎。 CRP 測試可幫助臨床醫生監測發炎的嚴重程度並相應調整治療計劃。隨著這些慢性病的盛行率增加，對 CRP 檢測作為監測工具的需求也在增加。發炎是心血管疾病 (CVD) 的公認危險因素，包括心臟病發作和中風。 CRP 水平升高與 CVD 風險增加有關。醫療保健提供者將 CRP 測試作為 CVD 整體風險評估的一部分，這可能會影響治療決策和生活方式建議。 CRP 水平會因細菌和病毒感染而升高。監測 CRP 水平有助於追蹤感染進展、評估抗菌療法的有效性以及確定患者何時康復。發炎和傳染病的日益普及促使人們對發炎在各種健康狀況中的作用進行了廣泛的研究。這項研究深入了解了 CRP 水平與疾病結果之間的關係，進一步強調了 CRP 檢測在臨床實踐中的重要性。
市場概況
預測期 2024-2028
2022 年市場規模 160101萬美元
2028 年市場規模 18.3528億美元
2023-2028 年年複合成長率 2.16%
成長最快的細分市場 免疫比濁分析
最大的市場 北美洲
  • 2.預防保健意識的提高：預防保健意識的提高極大影響了全球C反應蛋白（CRP）檢測市場的成長。預防性醫療保健的重點是在早期階段，甚至在症狀變得明顯之前，識別健康問題。在這種情況下，CRP 檢測是一種有價值的工具，可檢測臨床上可能尚不明顯的低度發炎。透過 CRP 檢測及早發現發炎可以及時干涉和管理，有可能預防潛在疾病的進展。預防性醫療保健通常涉及評估個人患某些疾病的風險。 CRP 測試可以提供有關個人發炎程度的資訊，有助於風險分層。 CRP 水平升高與心血管疾病等疾病的風險增加有關，因此 CRP 測試成為風險評估方案的重要組成部分。預防保健意識促進了針對個人特定風險因素和健康需求量身定做個人化健康計劃的概念。 CRP 測試增加了一個客觀的生物標記來指導這些個人化計劃，幫助醫療保健提供者設計干涉措施和生活方式改變，以解決發炎相關風險。預防保健通常強調改變生活方式以促進更好的健康結果。 CRP 測試結果可以作為一個有形的標記，激勵個人做出更健康的選擇，例如改善飲食、增加體力活動和戒菸。 CRP 檢測的可用性支援旨在幫助個人掌控自己健康的教育工作。公共衛生措施和篩檢計畫是預防性醫療保健工作的一部分。 CRP 測試可以整合到這些計劃中，以識別有發炎和相關疾病風險的個體。這種積極主動的方法可以實現早期干涉，減輕慢性病對醫療保健系統的負擔。
  • 3.老年人口和相關慢性病的增加：老年人口的增加和相關慢性病的盛行率在推動全球C反應蛋白（CRP）檢測市場的成長方面發揮著重要作用。老化與免疫系統的變化有關，使老年人更容易受到發炎的影響。慢性低度發炎（稱為發炎）在老年人中很常見，並導致各種與年齡相關的慢性疾病的發展。 CRP 測試是評估和監測這種慢性發炎的重要工具，可深入了解疾病風險和進展。老年人更容易罹患心血管疾病、糖尿病、骨關節炎和某些癌症等慢性疾病。 CRP 測試可幫助醫療保健提供者評估這些疾病的發炎成分，從而幫助診斷、管理和監測。老年人罹患心血管疾病的風險增加，而發炎是其發病機制的關鍵因素。 CRP 檢測用於評估心血管風險並指導治療決策，特別是在老年族群中，預防措施至關重要。老年人常同時患有多種慢性病。 CRP 測試可深入了解整體發炎狀態，幫助醫療保健提供者更有效地管理多種疾病並做出明智的治療選擇。由於免疫系統與年齡相關的變化，老年人更容易受到感染。 CRP 水平會因感染而升高，有助於評估和監測傳染病，這可能對老年人造成更嚴重的後果。老年族群的預防保健強調早期發現和干涉，以防止疾病進展並提高生活品質。 CRP 測試透過在早期階段檢測炎症，有助於及時干涉和個人化治療計劃，有助於這種方法。老年護理設施和長期照護機構通常為具有複雜健康需求的個人提供服務。 CRP 檢測是這些環境中監測居民健康、識別潛在感染和管理慢性病的寶貴工具。

主要市場挑戰

  • 1. CRP升高的非特異性：C反應蛋白（CRP）水平升高的非特異性對全球CRP檢測市場構成挑戰，主要是因為它可能導致診斷和治療決策的不確定性。 CRP 水平升高表明存在炎症，但它們並不能提供有關炎症根本原因的具體資訊。這種特異性的缺乏可能會導致診斷混亂，因為醫療保健提供者可能需要進行額外的測試來找出導致 CRP 升高的確切情況。因此，可能會延遲診斷實際的潛在疾病。 CRP 升高的非特異性性質可能會導致過度或不恰當地進行 CRP 檢測，從而導致不必要的醫療成本和資源利用。如果存在發炎但沒有臨床意義，醫療保健提供者可能會要求 CRP 檢測，這可能會導致過度診斷和過度使用醫療服務。
  • 2.不同的參考範圍：不同的實驗室和醫療機構可能使用不同的參考範圍

用於定義正常、升高和高 CRP 水平。這種不一致可能會導致醫療保健提供者和患者在解釋 CRP 測試結果時產生混淆。在一種情況下被認為正常的值在另一種情況下可能被歸類為升高，從而影響臨床決策。不同的參考範圍可能會不確定給定的 CRP 水平是否在正常範圍內或是否指示發炎。這種模糊性可能會對準確診斷發炎狀況造成挑戰，可能會延遲適當的治療和管理。建立 CRP 水平標準化參考範圍的努力有助於確保不同環境和實驗室之間的解釋一致。專業醫療組織可以根據臨床證據和共識提供解釋 CRP 檢測結果和定義參考範圍的指南和建議。

  • 3.外部因素的影響：外部因素對C反應蛋白（CRP）水平的影響可能對全球CRP檢測市場構成挑戰，影響CRP檢測結果的準確性、解釋和臨床實用性。 CRP 水平可能受到各種外部因素的影響，例如吸煙、肥胖和藥物。即使沒有明顯的炎症，這些因素也會導致 CRP 水平升高。醫療保健提供者可能會將升高的 CRP 水平誤認為是發炎的表現，而實際上這些升高是由外部影響引起的。當外部因素導致 CRP 水平升高時，醫療保健提供者可能會面臨區分 CRP 升高的真正發炎和非發炎原因的挑戰。這種複雜性可能會導致準確診斷和管理發炎狀況的困難。外部因素可能導致 CRP 檢測結果為假陽性或假陰性。例如，由於某些藥物的影響，發炎患者的 CRP 水平可能會正常。相反，由於非發炎因素而導致 CRP 水平升高的患者可能會被錯誤地認為有發炎相關疾病的風險。即使疾病狀態沒有變化，外部因素也可能導致 CRP 水平隨時間波動。這種不一致使得準確監測疾病進展並做出明智的治療決策變得具有挑戰性。

主要市場趨勢

  • 1.個人化醫療需求不斷成長：個人化醫療需求不斷成長是全球C反應蛋白（CRP）檢測市場的重要趨勢，影響其成長和應用。個人化醫療旨在根據患者的獨特特徵（包括基因組成、生活方式和生物標記概況）為其量身定做醫療治療和干涉措施。個人化醫療依賴生物標記來指導治療決策。 CRP 測試是評估發炎的一個有價值的生物標記物，發炎在多種疾病中發揮作用。醫療保健提供者利用 CRP 水平來幫助確定適合個別患者的最合適的治療策略。 CRP 測試透過評估個人罹患某些疾病（例如心血管疾病）的風險，有助於個人化醫療。 CRP 水平升高可能表示風險增加，促使醫療保健提供者實施針對患者風險狀況的預防措施和生活方式干涉措施。在個人化醫療中，持續監測疾病進展至關重要。 CRP 測試提供了一種監測發炎程度隨時間變化的方法，使醫療保健提供者能夠根據 CRP 水平和疾病狀態的變化調整治療計劃。個人化醫療涉及監測患者對治療的反應。 CRP 測試可幫助醫療保健提供者透過追蹤發炎程度的變化來評估干涉措施的有效性。如果 CRP 水平下降，可能表示對治療有積極反應。

細分市場洞察

檢測類型見解：

2022 年，免疫比濁分析領域主導了 C 反應蛋白檢測市場，預計在未來幾年將繼續擴張。免疫比濁分析具有高度準確度和精密度，使其成為臨床應用的理想選擇。它們相對容易使用，適合各種環境，包括醫院、診所和診斷實驗室。此外，它們具有成本效益，使其成為注重預算的組織的首選。免疫比濁測定透過測量溶液散射的光量來確定分析物的濃度。預計 2023 年至 2030 年該細分市場將經歷最高的年複合成長率 (CAGR)。

檢測範圍洞察：

2022 年，hs-CRP 3 細分市場主導 C 反應蛋白檢測市場，預計在未來幾年將持續成長。 hs-CRP 3 檢測比傳統 CRP 檢測更靈敏，使其能夠檢測較低水平的 CRP。這使得它們對於評估心血管疾病的風險特別有價值。這些檢測方法被臨床醫生廣泛接受並涵蓋許多臨床指引中。它們也相對具有成本效益，使其成為注重預算的組織的合適選擇。

疾病領域洞察：

2022 年，心血管疾病 (CVD) 領域主導 C 反應蛋白檢測市場，預計將繼續擴張。心血管疾病是全世界死亡的主要原因，CRP 水平升高與心臟病和中風等心血管疾病的風險增加有關。 CRP 檢測用於評估高風險族群（例如患有糖尿病、高血壓或高膽固醇的人）患 CVD 的風險。它也用於監測 CVD 治療的有效性，包括他汀類藥物和阿斯匹靈。

最終用途產業見解：

2022年，醫院領域主導了C反應蛋白檢測市場，預計未來幾年將持續成長。 COVID-19、冠狀動脈疾病 (CVD) 和癌症相關感染等疾病的日益普及導致住院人數增加，從而增加了對 CRP 檢測試劑盒的需求。

區域洞察

北美已成為全球 C 反應蛋白檢測市場的領導者。隨著心血管疾病發病率的不斷上升、持續不斷的產品推出、市場上成熟的參與者、尖端技術和完善的醫療保健系統，北美繼續推動 CRP 檢測市場的成長。

目錄

第 1 章：產品概述

  • 市場定義
  • 市場範圍
    • 涵蓋的市場
    • 研究年份
    • 主要市場區隔

第 2 章：研究方法

  • 研究目的
  • 基線方法
  • 主要產業夥伴
  • 主要協會和二手資料來源
  • 預測方法
  • 數據三角測量與驗證
  • 假設和限制

第 3 章：執行摘要

  • 市場概況
  • 主要市場細分概述
  • 主要市場參與者概述
  • 重點地區/國家概況
  • 市場促進因素、挑戰、趨勢概述

第 4 章：客戶之聲

第 5 章：全球 C 反應蛋白檢測市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依測定類型（免疫比濁測定、ELISA、化學發光免疫測定、其他）
    • 依檢測範圍（hs-CRP、傳統 CRP、cCRP）
    • 依疾病領域（心血管疾病、癌症、類風濕性關節炎、發炎性腸道疾病、子宮內膜異位症、紅斑性狼瘡等）
    • 依最終用途行業（診所和醫院、實驗室、輔助生活醫療設施、家庭護理、其他）
    • 按公司分類 (2022)
    • 按地區
  • 市場地圖

第 6 章：北美 C 反應蛋白檢測市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按類型
    • 按最終用途行業
    • 按國家/地區
  • 北美：國家分析
    • 美國
    • 墨西哥
    • 加拿大

第 7 章：歐洲 C 反應蛋白檢測市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按類型
    • 按最終用途行業
    • 按國家/地區
  • 歐洲：國家分析
    • 法國
    • 德國
    • 英國
    • 義大利
    • 西班牙

第 8 章：亞太地區 C 反應蛋白檢測市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按檢測類型
    • 按檢測範圍
    • 按疾病領域
    • 按最終用途行業
    • 按國家/地區
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲

第 9 章：南美洲 C 反應蛋白檢測市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按檢測類型
    • 按檢測範圍
    • 按疾病領域
    • 按最終用途行業
    • 按國家/地區
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第 10 章：中東和非洲 C 反應蛋白檢測市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按檢測類型
    • 按檢測範圍
    • 按疾病領域
    • 按最終用途行業
    • 按國家/地區
  • MEA：國家分析
    • 南非 C 反應蛋白檢測
    • 沙烏地阿拉伯 C 反應蛋白檢測
    • 阿拉伯聯合大公國 C 反應蛋白檢測

第 11 章：市場動態

  • 促進要素
  • 挑戰

第 12 章：市場趨勢與發展

  • 最近的發展
  • 產品發布
  • 併購

第 13 章：大環境分析

第 14 章：波特的五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 客戶的力量
  • 替代產品的威脅

第15章：競爭格局

  • 商業概覽
  • 公司概況
  • 產品與服務
  • 財務（上市公司）
  • 最近的發展
  • SWOT分析
    • Thermo Fisher Scientific, Inc.
    • F. Hoffmann-La Roche Ltd.
    • Danaher
    • Quest Diagnostics
    • Siemens Healthineers AG
    • Abbott
    • Merck KGaAA
    • Zoetis
    • Ortho Clinical Diagnostics
    • Getein Biotech, Inc.

第 16 章：策略建議

簡介目錄
Product Code: 17192

The Global C-reactive Protein Testing Market reached a value of USD 1601.01 Million in 2022 and is poised for robust growth during the forecast period, with a projected Compound Annual Growth Rate (CAGR) of 2.16% through 2028 an dis expected to reach USD 1835.28 Million in 2028. C-reactive Protein Testing, a laboratory examination, assesses the level of C-reactive protein in the bloodstream. This particular protein is synthesized by the liver in response to bodily inflammation. It forms an integral part of the body's innate immune reaction to infections, injuries, or other inflammatory stimuli. Typically, CRP testing involves a blood sample, and results are reported as milligrams of CRP per litre of blood (mg/L). Normal CRP levels are generally low, while elevated levels may signify ongoing inflammation or infection. It's important to note that factors like smoking, obesity, and certain medications can also influence CRP levels. CRP testing is commonly utilized as an inflammation marker in various medical contexts. Healthcare professionals frequently order CRP tests to aid in the diagnosis and monitoring of a range of conditions, including infections, autoimmune diseases, cardiovascular diseases, trauma or surgery, and treatment monitoring.

Key Market Drivers

  • 1. Growing Incidence of Inflammatory and Infectious Diseases: The increasing prevalence of inflammatory and infectious diseases significantly contributes to the expansion of the global C-reactive protein (CRP) testing market. These diseases often trigger an immune response, resulting in elevated CRP levels in the bloodstream. As the incidence of these diseases rises, healthcare providers increasingly require dependable diagnostic tools to detect and monitor inflammation. CRP testing offers a convenient and effective means of assessing inflammation levels, facilitating the diagnosis and management of various conditions. Timely detection of inflammation is pivotal for effective disease management and complications prevention. CRP testing allows for early identification of inflammation, enabling healthcare professionals to intervene before the condition worsens. This aligns with the broader trend of focusing on preventive healthcare and early disease detection. Many chronic diseases, such as rheumatoid arthritis, inflammatory bowel disease, and certain autoimmune disorders, involve ongoing inflammation. CRP testing helps clinicians monitor the severity of inflammation and adjust treatment plans accordingly. As the prevalence of these chronic conditions increases, the demand for CRP testing as a monitoring tool also grows. Inflammation is a recognized risk factor for cardiovascular diseases (CVD), including heart attacks and strokes. Elevated CRP levels have been associated with increased CVD risk. Healthcare providers use CRP testing as part of an overall risk assessment for CVD, which can influence treatment decisions and lifestyle recommendations. CRP levels can rise in response to infections, both bacterial and viral. Monitoring CRP levels can aid in tracking the progression of infections, evaluating the effectiveness of antimicrobial therapies, and determining when a patient is recovering. The increasing prevalence of inflammatory and infectious diseases has prompted extensive research into the role of inflammation in various health conditions. This research generates insights into the relationship between CRP levels and disease outcomes, further highlighting the importance of CRP testing in clinical practice.
Market Overview
Forecast Period2024-2028
Market Size 2022USD 1601.01 Million
Market Size 2028USD 1835.28 Million
CAGR 2023-20282.16%
Fastest Growing SegmentImmunoturbidimetric Assays
Largest MarketNorth America
  • 2. Increasing Awareness of Preventive Healthcare: The rising awareness of preventive healthcare significantly impacts the growth of the global C-reactive protein (CRP) testing market. Preventive healthcare focuses on identifying health issues at an early stage, even before symptoms become apparent. CRP testing serves as a valuable tool in this context by detecting low-grade inflammation that might not be clinically evident yet. Early detection of inflammation through CRP testing enables timely intervention and management, potentially preventing the progression of underlying diseases. Preventive healthcare often involves assessing an individual's risk of developing certain diseases. CRP testing can contribute to risk stratification by providing information about a person's inflammation levels. Elevated CRP levels are associated with an increased risk of conditions such as cardiovascular diseases, making CRP testing a valuable component of risk assessment protocols. The awareness of preventive healthcare promotes the idea of personalized health plans tailored to an individual's specific risk factors and health needs. CRP testing adds an objective biomarker to guide these personalized plans, helping healthcare providers design interventions and lifestyle modifications that address inflammation-related risks. Preventive healthcare often emphasizes lifestyle modifications to promote better health outcomes. CRP testing results can serve as a tangible marker that motivates individuals to make healthier choices, such as improving their diet, increasing physical activity, and quitting smoking. The availability of CRP testing supports educational efforts aimed at empowering individuals to take control of their health. Public health initiatives and screening programs are a part of preventive healthcare efforts. CRP testing can be integrated into these programs to identify individuals at risk of inflammatory conditions and related diseases. This proactive approach can lead to early interventions, reducing the burden of chronic diseases on healthcare systems.
  • 3. Increasing Geriatric Population and Associated Chronic Diseases: The rising geriatric population and the associated prevalence of chronic diseases play a significant role in driving the growth of the global C-reactive protein (CRP) testing market. Aging is associated with changes in the immune system, making older adults more susceptible to inflammation. Chronic low-grade inflammation, known as inflammaging, is common in the elderly and contributes to the development of various age-related chronic diseases. CRP testing is a valuable tool to assess and monitor this chronic inflammation, providing insights into disease risk and progression. The geriatric population is more prone to chronic diseases such as cardiovascular diseases, diabetes, osteoarthritis, and certain cancers. CRP testing helps healthcare providers evaluate the inflammatory component of these diseases, aiding in their diagnosis, management, and monitoring. Older adults are at an increased risk of cardiovascular diseases, and inflammation is a key factor in their pathogenesis. CRP testing is used to assess cardiovascular risk and guide treatment decisions, particularly in the elderly population, where preventive measures are crucial. Elderly individuals often have multiple chronic conditions simultaneously. CRP testing provides insights into the overall inflammatory status, helping healthcare providers manage multimorbidity more effectively and make informed treatment choices. Older adults are more susceptible to infections due to age-related changes in the immune system. CRP levels can rise in response to infections, aiding in the assessment and monitoring of infectious diseases, which can have more serious consequences in the elderly. Preventive healthcare in the geriatric population emphasizes early detection and intervention to prevent disease progression and improve quality of life. CRP testing contributes to this approach by detecting inflammation at an early stage, allowing for timely interventions and personalized treatment plans. Geriatric care facilities and long-term care settings often serve individuals with complex health needs. CRP testing is a valuable tool in these settings for monitoring residents' health, identifying potential infections, and managing chronic diseases.

Key Market Challenges

  • 1. Non-Specificity of Elevated CRP: The non-specificity of elevated C-reactive protein (CRP) levels poses a challenge to the global CRP testing market primarily because it can lead to uncertainties in diagnosis and treatment decisions. Elevated CRP levels indicate the presence of inflammation, but they do not provide specific information about the underlying cause of inflammation. This lack of specificity can lead to diagnostic confusion, as healthcare providers may need to conduct additional tests to pinpoint the exact condition causing the elevated CRP. As a result, there might be delays in diagnosing the actual underlying disease. The non-specific nature of CRP elevation can lead to situations where CRP testing is ordered excessively or inappropriately, contributing to unnecessary healthcare costs and resource utilization. Healthcare providers may order CRP tests in cases where inflammation is present but not clinically significant, potentially leading to overdiagnosis and overuse of healthcare services.
  • 2. Varied Reference Ranges: Different laboratories and healthcare facilities may use varying reference ranges

for defining normal, elevated, and high CRP levels. This inconsistency can lead to confusion among healthcare providers and patients when interpreting CRP test results. A value that is considered normal in one setting might be categorized as elevated in another, affecting clinical decision-making. Varied reference ranges can create uncertainty about whether a given CRP level is within a normal range or indicative of inflammation. This ambiguity can lead to challenges in diagnosing inflammatory conditions accurately, potentially delaying appropriate treatment and management. Efforts to establish standardized reference ranges for CRP levels can help ensure consistent interpretation across different settings and laboratories. Professional medical organizations can provide guidelines and recommendations for interpreting CRP test results and defining reference ranges based on clinical evidence and consensus.

  • 3. Influence of External Factors: The influence of external factors on C-reactive protein (CRP) levels can pose challenges to the global CRP testing market, affecting the accuracy, interpretation, and clinical utility of CRP test results. CRP levels can be affected by various external factors, such as smoking, obesity, and medications. These factors can lead to elevated CRP levels even in the absence of significant inflammation. Healthcare providers may misinterpret elevated CRP levels as indicative of inflammation when they are actually driven by external influences. When external factors contribute to elevated CRP levels, healthcare providers may face challenges in distinguishing between true inflammation and non-inflammatory causes of CRP elevation. This complexity can lead to difficulties in accurately diagnosing and managing inflammatory conditions. External factors can lead to false positive or false negative CRP test results. For example, a patient with inflammation might have normal CRP levels due to the influence of certain medications. Conversely, a patient with elevated CRP levels due to non-inflammatory factors might be wrongly considered at risk for inflammation-related conditions. External factors can lead to fluctuations in CRP levels over time, even in the absence of changes in disease status. This inconsistency can make it challenging to monitor disease progression accurately and make informed treatment decisions.

Key Market Trends

  • 1. Rising Demand for Personalized Medicine: The rising demand for personalized medicine is a significant trend in the global C-reactive protein (CRP) testing market, influencing its growth and application. Personalized medicine aims to tailor medical treatment and interventions to individual patients based on their unique characteristics, including genetic makeup, lifestyle, and biomarker profiles. Personalized medicine relies on biomarkers to guide treatment decisions. CRP testing serves as a valuable biomarker for assessing inflammation, which plays a role in various diseases. Healthcare providers use CRP levels to help determine the most appropriate treatment strategies for individual patients. CRP testing contributes to personalized medicine by assessing an individual's risk for certain diseases, such as cardiovascular diseases. Elevated CRP levels can indicate increased risk, prompting healthcare providers to implement preventive measures and lifestyle interventions tailored to the patient's risk profile. In personalized medicine, ongoing monitoring of disease progression is essential. CRP testing provides a means to monitor the level of inflammation over time, enabling healthcare providers to adjust treatment plans based on changes in CRP levels and disease status. Personalized medicine involves monitoring a patient's response to treatment. CRP testing helps healthcare providers gauge the effectiveness of interventions by tracking changes in inflammation levels. If CRP levels decrease, it may indicate a positive response to treatment.

Segmental Insights

Assay Type Insights:

In 2022, the immunoturbidimetric assays segment dominated the C-reactive Protein Testing market and is expected to continue its expansion in the years ahead. Immunoturbidimetric assays are highly accurate and precise, making them ideal for clinical applications. They are relatively easy to use and suitable for various settings, including hospitals, clinics, and diagnostic laboratories. Additionally, they are cost-effective, making them a preferred option for budget-conscious organizations. Immunoturbidimetric assays measure the amount of light scattered by a solution to determine the concentration of an analyte. This segment is projected to experience the highest Compound Annual Growth Rate (CAGR) from 2023 to 2030.

Detection Range Insight:

In 2022, the hs-CRP 3 segment dominated the C-reactive Protein Testing market and is expected to continue its growth in the coming years. hs-CRP 3 assays are more sensitive than conventional CRP assays, enabling them to detect lower levels of CRP. This makes them particularly valuable for assessing the risk of cardiovascular disease. These assays are widely accepted by clinicians and incorporated into many clinical guidelines. They are also relatively cost-effective, making them a suitable choice for budget-conscious organizations.

Disease Area Insight:

In 2022, the cardiovascular diseases (CVD) segment dominated the C-reactive Protein Testing market and is expected to continue its expansion. Cardiovascular diseases are the leading cause of death worldwide, and elevated CRP levels are associated with an increased risk of developing CVD, such as heart attacks and strokes. CRP testing is used to assess the risk of developing CVD in high-risk individuals, such as those with diabetes, high blood pressure, or high cholesterol. It is also employed to monitor the effectiveness of CVD treatment, including statins and aspirin.

End-Use Industry Insights:

In 2022, the hospital segment dominated the C-reactive Protein Testing market and is expected to continue its growth in the coming years. The increasing prevalence of diseases such as COVID-19, coronary artery disease (CVD), and cancer-related infections has led to higher hospital admissions, thereby increasing the demand for CRP test kits.

Regional Insights

North America has established itself as the leader in the global C-reactive Protein Testing Market. With a growing incidence of cardiovascular disease, a consistent stream of product introductions, well-established players in the market, cutting-edge technology, and a well-established healthcare system, North America continues to drive the growth of the CRP testing market.

Key Market Players

  • Thermo Fisher Scientific, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Danaher
  • Quest Diagnostics
  • Siemens Healthineers AG
  • Abbott
  • Merck KGaAA
  • Zoetis
  • Ortho Clinical Diagnostics
  • Getein Biotech, Inc.

Report Scope:

In this report, the Global C-reactive Protein Testing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

C-reactive Protein Testing Market, By Assay Type:

  • Immunoturbidimetric Assay
  • ELISA
  • Chemiluminescence Immunoassay
  • Others

C-reactive Protein Testing Market, By Detection Range:

  • hs-CRP
  • Conventional CRP
  • cCRP

C-reactive Protein Testing Market, By Disease Area:

  • Cardiovascular Diseases
  • Cancer
  • Rheumatoid Arthritis
  • Inflammatory Bowel Disease
  • Endometriosis
  • Lupus
  • Others

C-reactive Protein Testing Market, By End-User:

  • Hospitals & Clinics
  • Laboratories
  • Assisted Living Healthcare Facilities
  • Homecare
  • Others

Global C-reactive Protein Testing Market, By region:

  • North America
  • United States
  • Canada
  • Mexico
  • Asia-Pacific
  • China
  • India
  • South Korea
  • Australia
  • Japan
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

  • Company Profiles: Detailed analysis of the major companies present in the Global C-reactive Protein Testing Market.

Available Customizations:

  • Global C-reactive Protein Testing Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global C-reactive Protein Testing Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Assay Type (Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay, Others)
    • 5.2.2. By Detection Range (hs-CRP, Conventional CRP, cCRP)
    • 5.2.3. By Disease Area (Cardiovascular Disease, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus, Others)
    • 5.2.4. By End-Use Industry (Clinics and Hospitals, Laboratories, Assisted Living Healthcare Facilities, Homecare, Others)
    • 5.2.5. By Company (2022)
    • 5.2.6. By Region
  • 5.3. Market Map

6. North America C-reactive Protein Testing Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By End-Use Industry
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States C-reactive Protein Testing Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Assay Type
        • 6.3.1.2.2. By Detection Range
        • 6.3.1.2.3. By Disease Area
        • 6.3.1.2.4. By End-Use Industry
    • 6.3.2. Mexico C-reactive Protein Testing Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Assay Type
        • 6.3.2.2.2. By Detection Range
        • 6.3.2.2.3. By Disease Area
        • 6.3.2.2.4. By End-Use Industry
    • 6.3.3. Canada C-reactive Protein Testing Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Assay Type
        • 6.3.3.2.2. By Detection Range
        • 6.3.3.2.3. By Disease Area
        • 6.3.3.2.4. By End-Use Industry

7. Europe C-reactive Protein Testing Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By End-Use Industry
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France C-reactive Protein Testing Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Assay Type
        • 7.3.1.2.2. By Detection Range
        • 7.3.1.2.3. By Disease Area
        • 7.3.1.2.4. By End-Use Industry
    • 7.3.2. Germany C-reactive Protein Testing Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Assay Type
        • 7.3.2.2.2. By Detection Range
        • 7.3.2.2.3. By Disease Area
        • 7.3.2.2.4. By End-Use Industry
    • 7.3.3. United Kingdom C-reactive Protein Testing Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Assay Type
        • 7.3.3.2.2. By Detection Range
        • 7.3.3.2.3. By Disease Area
        • 7.3.3.2.4. By End-Use Industry
    • 7.3.4. Italy C-reactive Protein Testing Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Assay Type
        • 7.3.4.2.2. By Detection Range
        • 7.3.4.2.3. By Disease Area
        • 7.3.4.2.4. By End-Use Industry
    • 7.3.5. Spain C-reactive Protein Testing Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Assay Type
        • 7.3.5.2.2. By Detection Range
        • 7.3.5.2.3. By Disease Area
        • 7.3.5.2.4. By End-Use Industry

8. Asia-Pacific C-reactive Protein Testing Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Assay Type
    • 8.2.2. By Detection Range
    • 8.2.3. By Disease Area
    • 8.2.4. By End-Use Industry
    • 8.2.5. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China C-reactive Protein Testing Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Assay Type
        • 8.3.1.2.2. By Detection Range
        • 8.3.1.2.3. By Disease Area
        • 8.3.1.2.4. By End-Use Industry
    • 8.3.2. India C-reactive Protein Testing Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Assay Type
        • 8.3.2.2.2. By Detection Range
        • 8.3.2.2.3. By Disease Area
        • 8.3.2.2.4. By End-Use Industry
    • 8.3.3. South Korea C-reactive Protein Testing Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Assay Type
        • 8.3.3.2.2. By Detection Range
        • 8.3.3.2.3. By Disease Area
        • 8.3.3.2.4. By End-Use Industry
    • 8.3.4. Japan C-reactive Protein Testing Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Assay Type
        • 8.3.4.2.2. By Detection Range
        • 8.3.4.2.3. By Disease Area
        • 8.3.4.2.4. By End-Use Industry
    • 8.3.5. Australia C-reactive Protein Testing Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Assay Type
        • 8.3.5.2.2. By Detection Range
        • 8.3.5.2.3. By Disease Area
        • 8.3.5.2.4. By End-Use Industry

9. South America C-reactive Protein Testing Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Assay Type
    • 9.2.2. By Detection Range
    • 9.2.3. By Disease Area
    • 9.2.4. By End-Use Industry
    • 9.2.5. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil C-reactive Protein Testing Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Assay Type
        • 9.3.1.2.2. By Detection Range
        • 9.3.1.2.3. By Disease Area
        • 9.3.1.2.4. By End-Use Industry
    • 9.3.2. Argentina C-reactive Protein Testing Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Assay Type
        • 9.3.2.2.2. By Detection Range
        • 9.3.2.2.3. By Disease Area
        • 9.3.2.2.4. By End-Use Industry
    • 9.3.3. Colombia C-reactive Protein Testing Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Assay Type
        • 9.3.3.2.2. By Detection Range
        • 9.3.3.2.3. By Disease Area
        • 9.3.3.2.4. By End-Use Industry

10. Middle East and Africa C-reactive Protein Testing Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Assay Type
    • 10.2.2. By Detection Range
    • 10.2.3. By Disease Area
    • 10.2.4. By End-Use Industry
    • 10.2.5. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa C-reactive Protein Testing Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Assay Type
        • 10.3.1.2.2. By Detection Range
        • 10.3.1.2.3. By Disease Area
        • 10.3.1.2.4. By End-Use Industry
    • 10.3.2. Saudi Arabia C-reactive Protein Testing Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Assay Type
        • 10.3.2.2.2. By Detection Range
        • 10.3.2.2.3. By Disease Area
        • 10.3.2.2.4. By End-Use Industry
    • 10.3.3. UAE C-reactive Protein Testing Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value &
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Assay Type
        • 10.3.3.2.2. By Detection Range
        • 10.3.3.2.3. By Disease Area
        • 10.3.3.2.4. By End-Use Industry

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches
  • 12.3. Mergers & Acquisitions

13. PESTLE Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Product

15. Competitive Landscape

  • 15.1. Business Overview
  • 15.2. Company Snapshot
  • 15.3. Products & Services
  • 15.4. Financials (In case of listed companies)
  • 15.5. Recent Developments
  • 15.6. SWOT Analysis
    • 15.6.1. Thermo Fisher Scientific, Inc.
    • 15.6.2. F. Hoffmann-La Roche Ltd.
    • 15.6.3. Danaher
    • 15.6.4. Quest Diagnostics
    • 15.6.5. Siemens Healthineers AG
    • 15.6.6. Abbott
    • 15.6.7. Merck KGaAA
    • 15.6.8. Zoetis
    • 15.6.9. Ortho Clinical Diagnostics
    • 15.6.10. Getein Biotech, Inc.

16. Strategic Recommendations